Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

The companies will co-develop and co-promote a CAR T cell therapy in the United States.

Celgene, bluebird bio Partner on CAR-T Therapy

Novartis’ Sandoz is seeking approval of its biosimilar referencing Johnson & Johnson’s Remicade (infliximab) for all of Remicade’s indications across gastroenterology, rheumatology, and dermatology.

Novartis Gets Positive EMA Opinion on Biosimilar to J&J’s Remicade

EMA has recommended approval of the biosimilar for the same indications as Roche’s Herceptin (trastuzumab).

Amgen, Allergan Score Positive EMA Opinion on Biosimilar to Roche’s Herceptin

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

The delivery device and drug form should be considered when choosing a test method for identifying and measuring particulates.

Best Practices for Testing Foreign Particulate Matter in Inhaled Products

Revisions to chapters on glass containers and elastomeric closures were canceled following review of comments.

USP Cancels Revisions to Packaging Chapters

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

The FDA commissioner outlined the agency's initiatives to reward innovation and biosimilars development.

FDA's Gottlieb Hits Innovators, Insurers for Blocking Biosimilar Uptake

GlobalData reports the need to shift away from egg-based manufacturing of vaccines in light of influenza-related deaths.

GlobalData Reports Need to Shift to Newer Vaccine Manufacturing Technologies

Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.

ProBioGen and Surface Oncology Sign Second Antibody Manufacturing Program

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Assessing potential formulation and manufacturing issues in early development phases can improve a drug’s chances for success.

Can Early Development Strategies Avoid Later-Stage Disasters?

Jasdip S. Koner is senior formulation scientist at Aston Particle Technologies Ltd., Aston University, Birmingham, United Kingdom.

David A. Wyatt is chief operating officer at Aston Particle Technologies Ltd., Aston University, Birmingham, United Kingdom.

Eman Z. Dahmash is chief scientific officer at Aston Particle Technologies Ltd., Aston University, Birmingham, United Kingdom.

Afzal Mohammed is chief technical officer at Aston Particle Technologies Ltd., Aston University, Birmingham, United Kingdom.

Aston Particle Technologies has developed a technology that produces functionalized particles in a one-step, environmentally friendly process.